Your Health, We Care
Exkivity is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test , whose disease has progressed on or after platinum-based chemotherapy.
This indication is approved under accelerated approval based on overall response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
from FDA，2023.09
Mobocertinib is an oral targeted therapy primarily used for the treatment of loc···【more】
Release date：2026-02-26Recommended：30
Exkivity is suitable for specific non-small cell lung cancer(NSCLC).【more】
Release date：2026-01-06Recommended：28
Exkivity offers a new treatment option for NSCLC patients with EGFR exon 20 inse···【more】
Release date：2024-08-07Recommended：235
Exkivity provides a new treatment option for NSCLC patients with EGFR exon 20 in···【more】
Release date：2024-08-07Recommended：206
Exkivity is an innovative, oral, small molecule tyrosine kinase inhibitor (TKI) ···【more】
Release date：2024-08-07Recommended：199
